Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | MDM4 | O15151 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29792372 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL178744 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL29374829 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL30649315 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL29768913 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL29792120 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL117964 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL120511 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| Water SCHEMBL22070159 | 0.99 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| Water SCHEMBL31472478 | 0.99 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1959 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036916-A | Ruitalu Process for producing peptide | 哈尔滨吉象隆生物技术有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | ENZENE BIOSCIENCES LIMITED (IN) | 2026-04-14 | — | — | US | claimed |
| US-20250326796-A1 | PEPTIDE ANALOG WITH ANTI-INFLAMMATORY ACTIVITY AND ITS PREPARATION METHOD AND APPLICATION | SHANGHAI UNIVERSITY (CN) | 2025-10-23 | — | — | US | claimed |
| US-20250236655-A1 | PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | SHILPA PHARMA LIFESCIENCES LIMITED (IN) | 2025-07-24 | — | — | US | claimed |
| WO-2025130972-A1 | SYNTHETIC METHOD FOR TIRZEPATIDE | 深圳翰宇药业股份有限公司 | 2025-06-26 | — | — | WO | claimed |
| CN-115215925-B | Somatostatin type 2 receptor inhibitor, radionuclide complex thereof, preparation method and application | 上海益泰医药科技有限公司 | 2025-06-17 | — | — | CN | claimed |
| CN-120058862-A | Precursor compound of targeting human PD-L1, radiolabel and preparation method and application thereof | 厦门大学附属第一医院(厦门市第一医院、厦门市红十字会医院、厦门市糖尿病研究所) | 2025-05-30 | — | — | CN | claimed |
| CN-119350469-B | Method for synthesizing CAGRILINTIDE by large fragment SPPS-LPPS mixing method | 杭州诺澳生物医药科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| WO-2025098464-A1 | INTERMEDIATE FOR PREPARING GLUCAGON AND GLP-1 DUAL AGONIST AND PREPARATION METHOD THEREFOR | INNOVENT BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2025-05-15 | — | — | WO | claimed |
| CN-119959197-A | Interaction analysis method of 8:2 fluorotelomer alcohol-target protein based on confocal fluorescence imaging | 华中农业大学 | 2025-05-09 | — | — | CN | claimed |
| CN-112175067-B | Preparation method of teduglutide | 深圳市星银医药有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-113135988-B | Preparation method of thymosin beta 4 | 润辉生物技术（威海）有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-114262358-A | Preparation method of glutamine dipeptide | 苏州天马医药集团天吉生物制药有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-114249810-A | Synthetic method of somaglutide | 深圳翰宇药业股份有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-113121673-B | Method for preparing elcatonin by solid-liquid combination method | 润辉生物技术（威海）有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-114249808-A | Synthesis method of Cagrilintide | 杭州诺泰澳赛诺医药技术开发有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-113880936-B | Solid-phase synthesis method of abamectin | 浙江湃肽生物有限公司南京分公司 | 2022-03-29 | — | — | CN | claimed |
| CN-110746323-B | Industrial production method of efficient Fmoc-Glu (Otbu) -OH | 常州吉恩药业有限公司 | 2022-03-08 | — | — | CN | claimed |
| CN-110294800-B | Preparation method of somaglutide | 齐鲁制药有限公司 | 2022-03-04 | — | — | CN | claimed |
| EP-3941936-A2 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | Enzene Biosciences Ltd. (IN) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236655-A1 | PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | GLP1R, IAPP, VIP | MDM2 1541/4885TLR2 4425/4885MDM4 1231/4885 |
| US-20250326796-A1 | PEPTIDE ANALOG WITH ANTI-INFLAMMATORY ACTIVITY AND ITS PREPARATION METHOD AND APPLICATION | STING1, CGAS, VIP | MDM2 3166/4885TLR2 538/4885MDM4 1661/4885 |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | GLP1R, GIPR, GCG | MDM2 2390/4885TLR2 1915/4885MDM4 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.